We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gene Analysis Identifies People at Risk for Diabetes

By Biotechdaily staff writers
Posted on 05 Aug 2003
Researchers studying the genetic basis for diabetes have identified a group of 187 genes that are expressed differently in patients suffering from type 2 diabetes, and showed that 55 of these genes are expressed in asymptomatic individuals with a family history of the disease.

Investigators at Joslin Diabetes Center (Boston, MA, USA) used DNA microarray techniques to measure the expression of over 7,000 genes in muscle tissue from normal, diabetic, or pre-diabetic (having a family history of diabetes) Mexican-Americans, an ethnic group with a very high risk for diabetes. More...
They found that 187 genes were expressed differently between normals and diabetics, and that 166 genes were expressed differently between normals and pre-diabetics. A group of 55 genes were expressed differently in both groups.


Two of the 55 genes, PCG1-alpha and PCG1-beta, showed reduced expression that lead to the reduced activity of a larger group of genes involved in the metabolism of fats and carbohydrates. Many of the genes in the larger group encode for proteins in the mitochondria and are regulated by the NRF-1 gene. These findings were published in the July 8, 2003, issue of the Proceedings of the National Academy of Sciences.

"Knowing which genes are turned on or off in people before they develop diabetes is a key piece of information needed to solve the puzzle of diabetes, and to identify new ways to treat and prevent this devastating disease,” explained first author Dr. Mary-Elizabeth Patti, director of the genomics laboratory at Joslin Diabetes Center. "If we can identify people at high risk for diabetes and learn to prevent these changes from taking place, we may be able to find better methods for both treatment and prevention of diabetes.”



Related Links:
Joslin Diabetes Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.